Home > Insider Trading > Filing (0001415889-24-015678)

Filing Details

Accession Number:: 0001415889-24-015678
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-05 19:25:27
Reporting Period:: 2024-06-03

Accepted Time:: 2024-06-05 19:25:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1376355	Jay Lichter	C/O Janux Therapeutics, Inc. 10955 Vista Sorrento Parkway, Suite 200 San Diego CA 92130		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-06-03	677,279	$54.75	3,271,216	No	4	S	Indirect	By Avalon Ventures XI, L.P.
Common Stock	Disposition	2024-06-03	131,196	$54.75	633,673	No	4	S	Indirect	By Avalon BioVentures I, LP
Common Stock	Disposition	2024-06-03	691,525	$54.75	3,340,018	No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Avalon Ventures XI, L.P.
No	4	S	Indirect	By Avalon BioVentures I, LP
No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,583	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.
The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
The shares held directly by the Reporting Person prior to the transactions reported herein reflect the receipt of shares pursuant to the pro rata distributions in kind, effected by each of Avalon Ventures, ABV I and ABV SPV to its general partner and limited partners for no additional consideration, and the further pro rata distribution in kind by the general partners of ABV I and ABV SPV, for no additional consideration to their members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership from indirect to direct, which was exempt from reporting pursuant to Rule 16a-13.